Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
Key Highlights
- ➤86% of patients achieved at least 50% thyroid nodule volume reduction at six months
- ➤Median nodule volume reduction reached 72% at six months
- ➤ThyPRO-39 quality-of-life impact score improved 78% from baseline
- ➤82% of patients with baseline neck pressure or fullness had symptom resolution
- ➤No serious adverse events were reported through six months
Expert Statements
Ralph Tufano, MD, Director of the Multidisciplinary Thyroid and Parathyroid Center at Sarasota Memorial Hospital and principal investigator of PRECISE-BTN
“These six-month results are encouraging”
Ralph Tufano, MD, Director of the Multidisciplinary Thyroid and Parathyroid Center at Sarasota Memorial Hospital and principal investigator of PRECISE-BTN
“Volume reduction was apparent within the first month and continued through six months, and most patients experienced meaningful improvement in symptoms and quality of life. For patients with hyperfunctioning nodules, it is meaningful to see thyroid hormone levels improve while thyroid function is preserved. We look forward to the 12-month results.”
Thomas Fahey, MD, investigator at Weill Cornell Medicine
“It is exciting to see these results across both symptomatic and hyperfunctioning nodules, with the safety profile available with nsPFA treatment”
Thomas Fahey, MD, investigator at Weill Cornell Medicine
“A nonthermal, ultrasound-guided option that is safe around the nerves and surrounding critical structures is becoming a meaningful addition for appropriately selected patients.”
Kepal Patel, MD, investigator at NYU Langone Health
“Many patients come to us asking for a way to treat their nodules without surgery.”
Kepal Patel, MD, investigator at NYU Langone Health
“What they want is relief from their symptoms without putting thyroid function at risk, and these interim results are encouraging on both counts.”
Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences
“PRECISE-BTN was designed to evaluate whether the results of our early feasibility work could be reproduced in a rigorous, prospective multicenter setting, and these six-month interim data are an encouraging step toward that goal”
Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences
“We are particularly encouraged by the safety profile to date and by the results in both symptomatic and hyperfunctioning nodules. We thank our investigators, clinical sites, and study participants, and we look forward to reporting full results once all patients have completed 6-month follow-up.”
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no serious adverse events
Get started
Create a free account to read the full story.